Honored see Phare Bio highlighted by @Nature as part of its feature on six key developments in the fight against AMR.
We’re more energized than ever in our efforts to develop genAI-designed antibiotics and chart a new era of antibiotic discovery.
More: https://t.co/TlG9aKsztT
I’m excited to welcome Microsoft’s CSO @erichorvitz to the @PhareBio Board! Thank you Eric for your passion for rebuilding the antibiotic pipeline with AI. We’re thrilled to write this next chapter together.
Learn more: https://t.co/QSydYcDxyO
Antibiotics underpin modern medicine – until they stop working.
In a new piece for @gardp_amr's REVIVE platform, our CEO, Dr. @AkhilaKosaraju explores how AI could help rebuild the antibiotic pipeline with innovation outpacing resistance.
Read more: https://t.co/wu1u2ypgT1
The next decade of medicine will be decided by who leads in biotechnology.
At the @CFR_org annual lecture on science and technology, .@ARPA_HDirector Alicia Jackson joined @SenToddYoung and ARPA-H performer Dr. Akhila Kosaraju of @PhareBio to discuss why the United States must act now to pull ahead of our competitors in drug development and biomedical innovation.
Winning means turning breakthrough science into real treatments faster and more reliably than anyone else.
Biotechnology shapes our health, our economy, and our national security. The country that leads in advancing these critical technologies will set the global standard in the decades to come
ARPA-H was built for this moment, to move faster, take bigger risks, and ensure the future of medicine is led by the United States.
https://t.co/CJhiSaDn5m
Dr. Akhila Kosaraju of @PhareBio explains how AI is transforming antibiotic discovery -- predictive AI identifies promising compounds, while generative AI can design entirely new antibiotics from scratch. More in @ContagionLive: https://t.co/8F7dxxQLtI
In the final episode of the short series, Akhila Kosaraju, MD, talks about changing the development paradigm and moving away from reengineering molecules of existing antibiotic classes and towards creating new ones. #IDtwitter#Medtwitter
https://t.co/FgIND2zdXb
We’re so grateful to be part of @IAmBiotech’s #FightOfOurLives campaign -- sharing the stories behind biotech and the impact it can have. And we’re especially honored to be featured in Katy’s story.
Watch here: https://t.co/0AoOZwiomG
Today, BIO is launching Fight of Our Lives, a national campaign to build understanding of biotechnology, the people behind it, and the life-changing hope it creates for millions - because behind every breakthrough is a story of people, purpose, and the drive to find what comes next.
Biotechnology has transformed what’s possible - but many are still waiting for the next generation of solutions. Fight of Our Lives brings those real stories forward and reinforces what it takes to keep progress moving: a strong, predictable environment where innovation can thrive and reach those who need it most.
Hear the stories. See the impact. Explore the history. And join us in sharing the promise of American biotech - and the fight it will take to preserve it.
Learn more: https://t.co/4CUwHVutQo
#FightOfOurLives
In the second episode of this short series, Akhila Kosaraju, MD, talks about how Phare Bio and Basilea Pharmaceuticals are partnering to develop antimicrobials taking them from AI molecules to clinical trials. #IDtwitter#Medtwitter
https://t.co/FcROcKcB32
Dr. Akhila Kosaraju provides insights around how AI is moving towards an accelerated pace of antimicrobial development in hopes of getting molecules into clinical trials and approved much faster than the current paradigm. #IDtwitter#Medtwitter
https://t.co/LMExrnELT5
In a new @FastCompany op-ed, our CEO Dr. @AkhilaKosaraju explains why antibiotic resistance is a top global health challenge and how AI could unlock a new generation of antibiotics by cutting discovery and early preclinical timelines by up to 50-75%.
🔗 https://t.co/Ibs83c7s4o
At @Googleorg Demo Day, our CEO, Dr. @AkhilaKosaraju, highlighted how we’re redefining antibiotic discovery with open data + GenAI – so we can move science forward faster, together.
#AMR#AIForGood
Just wrapped an incredible Demo Day with @Googleorg!
Our CEO, Dr. @AkhilaKosaraju, showcased Phare Bio’s new GenAI agent for antibiotic discovery -- and attendees got to try it live at our booth. Grateful to be building alongside this inspiring community!
Big news at Phare! We just signed a first-of-its-kind partnership with Basilea to develop a next-gen AI-designed antibiotic.
This partnership is a historic first in antibiotics and represents a pivotal moment for the #AMR community.
https://t.co/OwMBk4RR4k
World AMR Awareness Week is here – and as superbugs keep evolving, the world needs real solutions.
At Phare Bio, we’re building a GenAI platform, generating and open-accessing drug-like datasets, and accelerating the development of new antibiotics to tackle this crisis.
#WAAW
This Wednesday! 📣
Our CEO, Dr. @AkhilaKosaraju, joins the @MilkenInstitute Future of Health Summit to discuss how AI, automation & global collaboration are reshaping the fight against #AMR.🦠
📍 Nov 5 | 9-10 AM ET | Washington, D.C.
🔗 https://t.co/RBdKD5ZEm5
#MIHealthSummit
#AMR is rising faster than we can respond. Per the @WHO, 1 in 6 infections is now resistant to #antibiotics -- a global crisis demanding bold innovation.
At Phare Bio, we’re using #AI to design new antibiotics and stay ahead of #superbugs.
🔗https://t.co/QM8Z2wd2mA
“Our thesis is that with AI and now generative AI, we will be taking fewer but better shots on goal,” said our CEO, Dr. @AkhilaKosaraju, in @CBCNews on MIT’s Collins Lab’s first-ever generative AI-designed antibiotics against #superbugs.
Read more: https://t.co/6BXJ5riYPS
“The data is out there. Let’s use it to save lives.”
In @thehill, our CEO, @AkhilaKosaraju, calls for open science + data-sharing to fight rapidly emerging antibiotic resistance.
👉 https://t.co/fEzVXhmO2E